Table 1.
Baseline Characteristics of Study Participants
| 1,25-dihydroxyvitamin D | P-value | |||
|---|---|---|---|---|
| < 15 pg/mL (n=367) |
15-22 pg/mL (n=366) |
> 22 pg/mL (n=366) |
||
| Age (y) | 67 ± 11 | 69 ± 11 | 71 ± 10 | <0.001 |
| Black Race | 31.9 | 29.2 | 34.0 | 0.6 |
| Diabetes | 62.1 | 55.7 | 46.6 | <0.001 |
| Hypertension | 96.5 | 97.2 | 95.6 | 0.5 |
| CVD | 57.5 | 56.0 | 56.7 | 0.8 |
| BMI (kg/m2) | 28.9 ± 5.4 | 27.8 ± 4.5 | 27.1 ± 4.4 | <0.001 |
| Systolic blood pressure (mmHg) | 146 ± 24 | 144 ± 23 | 140 ± 21 | <0.001 |
| eGFR (mL/min/1.73m2) | 16 ± 5.3 | 18 ± 6.2 | 20 ± 6.8 | <0.001 |
| Medication ACE Inhibitor Beta-blockers Lipid-lowering |
43.5 61.8 61.8 |
41.8 60.2 53.8 |
38.0 56.5 54.0 |
0.1 0.1 0.03 |
| Albumin (g/dL) | 3.9 ± 0.5 | 4.1 ± 0.5 | 4.2 ± 0.5 | <0.001 |
| Total Cholesterol (mg/dL) | 174 ± 46 | 171 ± 43 | 176 ± 41 | 0.6 |
| HDL Cholesterol (mg/dL) | 41 ± 12 | 43 ± 17 | 44 ± 15 | 0.01 |
| LDL Cholesterol (mg/dL) | 96 ± 33 | 93 ± 31 | 95 ± 32 | 0.9 |
| Triglycerides (mg/dL) | 193 ± 154 | 179 ± 137 | 181 ± 112 | 0.2 |
Values for continuous variables are expressed as mean ± standard deviation; values for categorical variables given as number (percentage).
CVD= cardiovascular disease; BMI=body mass index; ACE = angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; eGFR= estimated glomerular filtration rate; HDL= high density lipoprotein; LDL= low density lipoprotein; iPTH=intact parathyroid hormone; FGF23=fibroblast growth factor-23.
conversion factors for units: eGFR in ml/min/1.73m2 to mL/s/1.73m2 ×0.01667; serum 25(OH)D in ng/mL to nmol/L ×2.496; 1,25(OH)2D in pg/mL to pmol/L ×2.6; serum calcium in mg/dL to mmol/L × 0.2495; serum phosphorus in mg/dL to mmol/L ×0.3229; Serum hemoglobin and albumin in g/dL to g/L × 10; serum cholesterol mg/dL in mmol/L × 0.02586; serum triglycerides in mg/dL to mmol/L × 0.01129.